当前位置:
X-MOL 学术
›
J. Infect. Dis.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023
The Journal of Infectious Diseases ( IF 5.0 ) Pub Date : 2024-06-04 , DOI: 10.1093/infdis/jiae303
Jingrong Ye 1 , Yuan Dong 2 , Yun Lan 3 , Jing Chen 1 , Ying Zhou 4 , Jinjin Liu 5 , Dan Yuan 6 , Xinli Lu 7 , Weigui Guo 8 , Minna Zheng 9 , Hong Yang 10 , Xiao Song 11 , Cong Liu 12 , Quanhua Zhou 13 , Chenli Zheng 14 , Qi Guo 15 , Xiaohui Yang 16 , Lincai Zhang 17 , Zhangwen Ge 18 , Lifeng Liu 19 , Fengting Yu 20 , Yang Han 21 , Huihuang Huang 22 , Mingqiang Hao 1 , Yuhua Ruan 23 , Jianjun Wu 24 , Jianjun Li 25 , Qiang Chen 1 , Zhen Ning 2 , Xuemei Ling 3 , Chang Zhou 6 , Xuangu Liu 8 , Jianyun Bai 9 , Ya Gao 10 , Xue Tong 11 , Kangping Zhou 12 , Fanghua Mei 12 , Zhengrong Yang 14 , Ao Wang 15 , Wei Wei 16 , Ruijuan Qiao 17 , Xinhua Luo 18 , Xiaojie Huang 19 , Juan Wang 1 , Xin Shen 2 , Fengyu Hu 3 , Linglin Zhang 6 , Wei Tan 14 , Jixiang Fan 15 , Aixia Tu 17 , Guolong Yu 26 , Yong Fang 27 , Shufang He 1 , Xin Chen 2 , Donglin Wu 15 , Xinhui Zhang 28 , Ruolei Xin 1 , Xin He 27 , Xianlong Ren 1 , Conghui Xu 1 , Yanming Sun 1 , Yang Li 1 , Guowu Liu 1 , Xiyao Li 1 , Junyi Duan 19 , Tao Huang 19 , Yiming Shao 23 , Yi Feng 23 , Qichao Pan 2 , Bin Su 19 , Tianjun Jiang 22 , Hongxin Zhao 20 , Tong Zhang 19 , Faqing Chen 17 , Bing Hu 16 , Hui Wang 15 , Jin Zhao 14 , Kun Cai 12 , Wei Sun 11 , Baicheng Gao 10 , Tielin Ning 9 , Shu Liang 6 , Yuqi Huo 5 , Gengfeng Fu 4 , Feng Li 3 , Yi Lin 2, 29, 30 , Hui Xing 23 , Hongyan Lu 1
The Journal of Infectious Diseases ( IF 5.0 ) Pub Date : 2024-06-04 , DOI: 10.1093/infdis/jiae303
Jingrong Ye 1 , Yuan Dong 2 , Yun Lan 3 , Jing Chen 1 , Ying Zhou 4 , Jinjin Liu 5 , Dan Yuan 6 , Xinli Lu 7 , Weigui Guo 8 , Minna Zheng 9 , Hong Yang 10 , Xiao Song 11 , Cong Liu 12 , Quanhua Zhou 13 , Chenli Zheng 14 , Qi Guo 15 , Xiaohui Yang 16 , Lincai Zhang 17 , Zhangwen Ge 18 , Lifeng Liu 19 , Fengting Yu 20 , Yang Han 21 , Huihuang Huang 22 , Mingqiang Hao 1 , Yuhua Ruan 23 , Jianjun Wu 24 , Jianjun Li 25 , Qiang Chen 1 , Zhen Ning 2 , Xuemei Ling 3 , Chang Zhou 6 , Xuangu Liu 8 , Jianyun Bai 9 , Ya Gao 10 , Xue Tong 11 , Kangping Zhou 12 , Fanghua Mei 12 , Zhengrong Yang 14 , Ao Wang 15 , Wei Wei 16 , Ruijuan Qiao 17 , Xinhua Luo 18 , Xiaojie Huang 19 , Juan Wang 1 , Xin Shen 2 , Fengyu Hu 3 , Linglin Zhang 6 , Wei Tan 14 , Jixiang Fan 15 , Aixia Tu 17 , Guolong Yu 26 , Yong Fang 27 , Shufang He 1 , Xin Chen 2 , Donglin Wu 15 , Xinhui Zhang 28 , Ruolei Xin 1 , Xin He 27 , Xianlong Ren 1 , Conghui Xu 1 , Yanming Sun 1 , Yang Li 1 , Guowu Liu 1 , Xiyao Li 1 , Junyi Duan 19 , Tao Huang 19 , Yiming Shao 23 , Yi Feng 23 , Qichao Pan 2 , Bin Su 19 , Tianjun Jiang 22 , Hongxin Zhao 20 , Tong Zhang 19 , Faqing Chen 17 , Bing Hu 16 , Hui Wang 15 , Jin Zhao 14 , Kun Cai 12 , Wei Sun 11 , Baicheng Gao 10 , Tielin Ning 9 , Shu Liang 6 , Yuqi Huo 5 , Gengfeng Fu 4 , Feng Li 3 , Yi Lin 2, 29, 30 , Hui Xing 23 , Hongyan Lu 1
Affiliation
Background National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. Methods We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. Results Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1–4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%–2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%–1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%–1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%–4.52%) in 2018 to 5.39% (95% CI, 4.33%–6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%–.38%) of 4205 PWH. Conclusions Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.
更新日期:2024-06-04